Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GenSight Biologics    SIGHT   FR0013183985

GENSIGHT BIOLOGICS (SIGHT)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 05:35:16 pm
3.74 EUR   -2.35%
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
3.77(c) 3.71(c) 3.97(c) 3.83(c) 3.74(c) Last
660 421 501 280 762 680 390 267 468 823 Volume
+4.14% -1.59% +7.01% -3.53% -2.35% Change
More quotes
Financials (EUR)
Sales 2018 13,6 M
EBIT 2018 -11,6 M
Net income 2018 -14,1 M
Finance 2018 39,2 M
Yield 2018 -
Sales 2019 3,63 M
EBIT 2019 -28,7 M
Net income 2019 -28,7 M
Debt 2019 6,10 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 4,09x
EV / Sales2019 27,8x
Capitalization 94,9 M
More Financials
Company
GenSight Biologics specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives. At the end of 2017, the company had a portfolio of 2 products, including 1 in phase III clinical development (GS010 for the treatment of Leber... 
More about the company
Surperformance© ratings of GenSight Biologics
Trading Rating : Investor Rating :
More Ratings
Latest news on GENSIGHT BIOLOGICS
10/31GENSIGHT BIOLOGICS : Corporate presentation, November, 2018
PU
10/24GENSIGHT BIOLOGICS : Reports its Cash Position as of September 30, 2018
PU
07/25GENSIGHT BIOLOGICS : Half-year results
CO
06/30GENSIGHT BIOLOGICS : Half-year report
CO
06/20GENSIGHT BIOLOGICS : Key Opinion Leaders highlight GS010 efficacy and patient be..
PU
04/25GENSIGHT BIOLOGICS : 1st quarter earnings
CO
04/06GENSIGHT BIOLOGICS : falls after Phase III neuropathy miss
AQ
04/05GENSIGHT BIOLOGICS : announces topline results from REVERSE Phase III clinical t..
AQ
04/05GENSIGHT BIOLOGICS : Placebo Beats a Gene Therapy for Blindness in a Phase 3 Tri..
AQ
01/25GENSIGHT BIOLOGICS : Appoints Julio Benedicto as Vice President of Marketing
PU
More news
Sector news : Bio Therapeutic Drugs
12/14FDA Approves Herceptin Biosimilar Herzuma
DJ
12/13Lilly, Incyte Get FDA Fast-Track Designation for Baricitinib in Systemic Lupu..
DJ
12/10Almost half of S&P 500 stocks in a bear market
RE
12/10ROCHE : Gilead Sciences snares Roche veteran O'Day as CEO
RE
12/10LONZA : to Establish Biomanufacturing Base in China
DJ
More sector news : Bio Therapeutic Drugs
Chart GENSIGHT BIOLOGICS
Duration : Period :
GenSight Biologics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENSIGHT BIOLOGICS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 8,03 €
Spread / Average Target 110%
EPS Revisions
Managers
NameTitle
Bernard Jacques Alex Gilly Chief Executive Officer & Director
Michael S. Wyzga Independent Chairman
Thomas Gidoin Chief Financial Officer
Barrett Katz Chief Medical Officer
Harvey N. Masonson Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
GENSIGHT BIOLOGICS-38.03%108
GILEAD SCIENCES-5.99%87 125
VERTEX PHARMACEUTICALS17.08%44 319
REGENERON PHARMACEUTICALS0.68%40 244
GENMAB3.74%9 984
SAREPTA THERAPEUTICS INC119.30%8 154